Scarica l'app Stockscreener
85.95
1.65%
-1.44
Dopo l'orario di chiusura:
85.80
-0.15
-0.17%
Precedente Chiudi:
$87.39
Aprire:
$85.86
Volume 24 ore:
767.35K
Relative Volume:
0.74
Capitalizzazione di mercato:
$4.93B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-29.04
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
+10.49%
1M Prestazione:
-1.67%
6M Prestazione:
-1.89%
1 anno Prestazione:
-34.58%
Intervallo 1D:
$85.16
$88.29
Intervallo di 1 settimana:
$76.88
$102.80
Portata 52W:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
85.95 | 5.02B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
125.80 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.84 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.61 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.42 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.15 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Can Glaukos Corporation (6GJ) stock double in coming years2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Custom watchlist performance reports with Glaukos CorporationJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Will Glaukos Corporation stock attract more institutional investorsTrade Entry Summary & Safe Capital Allocation Plans - newser.com
Why Glaukos Corporation stock appears on watchlistsQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
How higher bond yields impact Glaukos Corporation stockWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Will Glaukos Corporation continue its uptrendMarket Risk Report & Short-Term High Return Ideas - newser.com
Key metrics from Glaukos Corporation’s quarterly dataPortfolio Performance Summary & AI Based Buy/Sell Signal Reports - newser.com
Can Glaukos Corporation stock expand revenue streamsRate Cut & Consistent Growth Stock Picks - newser.com
Risk vs reward if holding onto Glaukos CorporationTrade Performance Summary & Comprehensive Market Scan Reports - newser.com
What risks investors should watch in Glaukos Corporation stockMarket Growth Report & Reliable Trade Execution Plans - newser.com
Will Glaukos Corporation (6GJ) stock remain on Wall Street radar2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Why Glaukos Corporation stock remains on buy listsIPO Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Backtesting results for Glaukos Corporation trading strategies2025 Market Overview & Fast Gain Swing Alerts - newser.com
Is Glaukos Corporation stock dividend yield sustainableWeekly Profit Report & Community Driven Trade Alerts - newser.com
Is Glaukos Corporation stock overvalued by current metrics2025 Market Outlook & Weekly High Conviction Ideas - newser.com
How Glaukos Corporation stock performs in stagflationWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Glaukos Announces Participation in Upcoming Investor Conferences - The AI Journal
Zweig DiMenna Associates LLC Sells 52,200 Shares of Glaukos Corporation $GKOS - MarketBeat
Is Glaukos Corporation stock a bargain at current levelsTrade Ideas & AI Driven Stock Reports - newser.com
What high frequency data says about Glaukos CorporationMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Is Glaukos Corporation stock attractive for income investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
FY2025 Earnings Forecast for Glaukos Issued By William Blair - MarketBeat
How strong is Glaukos Corporation stock earnings growthQuarterly Profit Review & Real-Time Buy Signal Notifications - newser.com
How Glaukos Corporation (6GJ) stock responds to job market shiftsJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com
How Glaukos Corporation stock responds to policy changesJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
Glaukos (GKOS) Is Up 17.9% After FDA Approval of Epioxa and Record Q3 Results Has the Bull Case Changed? - simplywall.st
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth - MSN
Why analysts maintain buy rating on Glaukos Corporation (6GJ) stockEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com
Can Glaukos Corporation (6GJ) stock sustain free cash flow2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Is Glaukos Corporation stock cheap by valuation metricsTrend Reversal & Stepwise Trade Execution Plans - newser.com
Glaukos Corporation $GKOS Shares Purchased by Bessemer Group Inc. - MarketBeat
Published on: 2025-11-02 03:24:12 - newser.com
Will Glaukos Corporation stock keep outperforming rivals2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Can Glaukos Corporation stock sustain free cash flow growth2025 Price Targets & Long Hold Capital Preservation Tips - newser.com
William Blair Issues Negative Forecast for Glaukos Earnings - MarketBeat
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):